FORA Capital LLC Has $1.16 Million Holdings in Humana Inc. (NYSE:HUM)

FORA Capital LLC trimmed its position in shares of Humana Inc. (NYSE:HUM) by 87.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,584 shares of the insurance provider’s stock after selling 32,933 shares during the quarter. FORA Capital LLC’s holdings in Humana were worth $1,163,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in HUM. Dodge & Cox lifted its stake in Humana by 106.7% in the fourth quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider’s stock valued at $2,587,345,000 after acquiring an additional 5,264,045 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Humana by 15.8% in the 4th quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider’s stock valued at $3,254,899,000 after purchasing an additional 1,751,857 shares during the last quarter. Norges Bank bought a new stake in Humana in the fourth quarter worth $416,202,000. Pzena Investment Management LLC increased its position in Humana by 44.0% during the fourth quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider’s stock worth $915,736,000 after buying an additional 1,103,132 shares during the last quarter. Finally, Boston Partners lifted its position in shares of Humana by 435.8% in the fourth quarter. Boston Partners now owns 1,098,702 shares of the insurance provider’s stock worth $279,236,000 after buying an additional 893,637 shares during the last quarter. Institutional investors own 92.38% of the company’s stock.

Humana Stock Down 1.5 %

NYSE HUM opened at $249.67 on Friday. Humana Inc. has a 1-year low of $213.31 and a 1-year high of $406.46. The company has a market capitalization of $30.13 billion, a price-to-earnings ratio of 25.09, a PEG ratio of 2.05 and a beta of 0.49. The stock’s 50 day moving average is $265.21 and its two-hundred day moving average is $270.30. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.07 by $1.51. Humana had a net margin of 1.02% and a return on equity of 11.70%. The business had revenue of $32.11 billion during the quarter, compared to analysts’ expectations of $32 billion. During the same quarter last year, the company posted $7.23 EPS. The firm’s revenue for the quarter was up 8.4% on a year-over-year basis. Equities analysts forecast that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be given a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, June 27th. This represents a $3.54 annualized dividend and a yield of 1.42%. Humana’s dividend payout ratio (DPR) is 25.04%.

Analysts Set New Price Targets

A number of brokerages recently weighed in on HUM. Truist Financial raised their price objective on Humana from $290.00 to $325.00 and gave the company a “hold” rating in a research note on Friday, April 11th. Mizuho boosted their price objective on shares of Humana from $305.00 to $316.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 9th. Piper Sandler raised their target price on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research note on Wednesday, January 15th. Barclays boosted their target price on shares of Humana from $270.00 to $322.00 and gave the stock an “equal weight” rating in a research report on Friday, April 11th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $290.00 price objective on shares of Humana in a research note on Thursday, May 1st. Seventeen equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $287.76.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.